Anthracyclines are the cornerstone of many chemotherapy regimens for a variety of cancers.
Unfortunately, their use is limited by a cumulative dose-dependent cardiotoxicity. Despite …

Purpose Carbonyl reductases (CBRs) catalyze reduction of anthracyclines to cardiotoxic
alcohol metabolites. Polymorphisms in CBR1 and CBR3 influence synthesis of these …

The aldo-keto reductase (AKR) superfamily comprises enzymes that catalyze redox
transformations involved in biosynthesis, intermediary metabolism, and detoxification …

Background—A significant number of patients treated with anthracyclines develop
cardiotoxicity (anthracycline-induced cardiotoxicity [ACT]), mainly presenting as arrhythmias …

Many clinical studies involving anti-tumor agents neglect to consider how these agents are
metabolized within the host and whether the creation of specific metabolites alters drug …

Many antitumor drugs cause “on treatment” cardiotoxicity or introduce a measurable risk of
delayed cardiovascular events. Doxorubicin and other anthracyclines cause congestive …

A genetically engineered apoferritin variant consisting of 24 heavy-chain subunits (HFn) was
produced to achieve a cumulative delivery of an antitumor drug, which exerts its cytotoxic …

The clinical use of doxorubicin and other antitumor anthracyclines is limited by a dose-
related risk of cardiomyopathy and heart failure which may occur “on treatment” or any time …

Anthracyclines are among the most effective anticancer drugs ever developed.
Unfortunately, their clinical use is severely limited by the development of a progressive dose …

Haematopoietic cell transplantation (HCT) survivors are at increased risk for develo**
congestive heart failure (CHF), primarily due to pre‐HCT exposure to anthracyclines. We …